ASH 2023: Leukemias and MDS

CE / CME

Key Studies in Leukemias and Myelodysplastic Syndromes: Independent Conference Coverage of ASH 2023

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: March 06, 2024

Expiration: March 05, 2025

Eunice S. Wang
Eunice S. Wang, MD

Activity

Progress
1 2
Course Completed

References

  1. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454-464.
  2. Erba, HP, Montesinos P, Kim HJ, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1571-1583.
  3. Perl AE, Erba HP, Montesinos P, et al. Quantum-First trial: FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–specific measurable residual disease (MRD) clearance assessed through induction (IND) and consolidation (CONS) is associated with improved overall survival (OS) in newly diagnosed (nd) FLT3-ITD+ AML patients (pts). Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 832.
  4. Dinardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617-629.
  5. Pratz KW, Jonas BA, Pullarkat VA, et al. Long-term follow-up of the phase 3 VIALE-A clinical trial of venetoclax plus azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Presented at: 2022 American Society of Hematology Annual Meeting and Exposition; December 10-13, 2022. Abstract 615.
  6. Garciaz S, Bertoli S, Sallman DA, et al. Acute myeloid leukemia patients who stopped venetoclax or/and azacytidine for other reasons than progression have a prolonged treatment free remission and overall survival. A Filo study. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 161.
  7. Yilmaz M, Muftuoglu M, DiNardo CD, et al. Phase I/II study of quizartinib, venetoclax, and decitabine triple combination in FLT3-ITD mutated AML. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 158.
  8. Zeiser R, Devillier R, Mico MC, et al. TIM-3 inhibitor sabatolimab for patients with acute myeloid leukemia (AML) with measurable residual disease (MRD) detected after allogeneic stem cell transplantation (AlloSCT): preliminary findings from the phase Ib/II stimulus-AML2 study. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 59.
  9. Litzow MR, Sun Z, Paietta E, et al. Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with B-lineage acute lymphoblastic leukemia in measurable residual disease negative remission: results from the ECOG-ACRIN E1910 randomized phase III National Cooperative Clinical Trials Network trial. Presented at: 2022 American Society of Hematology Annual Meeting and Exposition; December 10-13, 2022. Abstract LBA-1.
  10. Aldoss I, Issa GC, Thirman M, et al. Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemia: topline efficacy and safety results from the pivotal AUGMENT-101 phase 2 study. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract LBA-5.
  11. Issa GC, Aldoss I, DiPersio J, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615:920-924.
  12. Jabbour E, Searle E, Abdul-Hay M, et al. A first-in-human phase 1 study of the menin-KMT2A (MLL1) inhibitor JNJ-75276617 in adult patients with relapsed/refractory acute leukemia harboring KMT2A or NPM1 alterations. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 57.
  13. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: chronic myeloid leukemia. v.2.2024. nccn.org. Accessed February 26, 2024.
  14. National Institutes of Health, National Cancer Institute. Chronic myelogenous leukemia treatment. cancer.gov/types/leukemia/patient/cml-treatment-pdq. Accessed February 26, 2024.
  15. Asciminib [prescribing information]. East Hanover, NJ: Novartis; 2023.
  16. Yeung DT, Shanmuganathan N, Reynolds J, et al. excellent early and major molecular responses observed with asciminib treatment for CP-CML: results from the ALLG CML13 ASCEND-CML study. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 865.
  17. National Organization for Rare Disorders. Acute promyelocytic leukemia. rarediseases.org/rare-diseases/acute-promyelocytic-leukemia. Accessed February 26, 2024.
  18. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: acute myeloid leukemia. v.6.2023. nccn.org. Accessed February 26, 2024.
  19. Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133:1630-1643.
  20. Kumana CR, Mak R, Kwong Y-L, et al. Resurrection of oral arsenic trioxide for treating acute promyelocytic leukaemia: a historical account from bedside to bench to bedside. Front Oncol. 2020;10:1294.
  21. Gill H, Yim R, Chin L, et al. An entirely oral regimen of oral-arsenic trioxide/all-trans retinoic acid/ascorbic acid in newly-diagnosed acute promyelocytic leukaemia (APL): updated results of an ongoing multicentre trial. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 157.
  22. Luspatercept [prescribing information]. Summit, NJ: Bristol Myers Squibb Co; 2023.
  23. Platzbecker U, Della Porta MG, Santini V, et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet. 2023;402:373-385.
  24. Garcia-Manero G, Platzbecker U, Santini V, et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive patients (Pts) with transfusion-dependent (TD) lower-risk myelodysplastic syndromes (LR-MDS): full analysis of the COMMANDS trial. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 193.
  25. Zeidan AM, Platzbecker U, Santini V, et al. IMerge: results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA). Presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 7004.
  26. Komrokji RS, Santini V, Fenaux P, et al. Efficacy of imetelstat in achieving red blood cell transfusion independence (RBC-TI) across different risk subgroups in patients with lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis-stimulating agents (ESAs) in IMerge phase 3 study. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 194.
  27. Platzbecker U, Santini V, Fenaux P, et al. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;403:249-260.